Search
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
Indocyanine green
go.drugbank.com/drugs/DB16024ApprovedInvestigationalWithdrawnCategories: Compounds used in a research, industrial, or household settingAmibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
RH-1
go.drugbank.com/drugs/DB04090InvestigationalRH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.
MVA3000
go.drugbank.com/drugs/DB05040ExperimentalMVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or
2X-121
go.drugbank.com/drugs/DB16063Investigational2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the … 2X-121 DRP).
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalThere are multiple routes for administration of omega interferon: injection, an implantable subcutaneous drug delivery system, and an oral formulation. … It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.
Synonyms: IFN-ωPrednisolone sodium metazoate
go.drugbank.com/drugs/DB05340InvestigationalReleasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis. … ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeATB-346
go.drugbank.com/drugs/DB15377InvestigationalATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).